Stay updated on Adj Immunotherapy Post Salvage Surgery in HNSCC Clinical Trial

Sign up to get notified when there's something new on the Adj Immunotherapy Post Salvage Surgery in HNSCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adj Immunotherapy Post Salvage Surgery in HNSCC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the study record related to Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma, specifically in the phase 2 trial evaluating the efficacy and toxicity of Nivolumab alone and the combination of Nivolumab and Ipilimumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:23:23.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for the study, specifying the health conditions and prior treatments required for participation. This change provides more specific information about the inclusion and exclusion criteria for potential participants.
    Difference
    52%
    Check dated 2024-05-22T19:34:16.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:35:50.000Z thumbnail image

Stay in the know with updates to Adj Immunotherapy Post Salvage Surgery in HNSCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adj Immunotherapy Post Salvage Surgery in HNSCC Clinical Trial page.